Professor Phil Darcy is currently a NHMRC Senior Research Fellow and Group Leader at the Peter MacCallum Cancer Centre. His laboratory focuses on developing novel T cell based immunotherapy approaches for cancer in preclinical mouse models and translating this into patients. Specifically, he is focused on the development of gene modified mouse and human T cells expressing chimeric antigen receptors (CARs) that can effectively target and eradicate cancer in mice. A Phase I clinical trial leading from this work was recently completed at the Peter MacCallum Cancer Centre in patients with acute myeloid leukaemia which represented a first in Australia using this approach and another trial using this approach in non-small cell lung carcinoma patients is underway. His laboratory is also focused on development of combined immune based therapies for cancer.